{
    "organizations": [],
    "uuid": "ea737e826432ca9fb63cbb8c03fa9c62e61ef4cd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-xenon-presents-positive-xen1101-tm/brief-xenon-presents-positive-xen1101-tms-pharmacodynamic-phase-1-data-at-14th-eilat-conference-idUSFWN1SM0PD",
    "ord_in_thread": 0,
    "title": "BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Xenon Pharmaceuticals Inc:\n* XENON PRESENTS POSITIVE XEN1101 TMS PHARMACODYNAMIC PHASE 1 DATA AT 14TH EILAT CONFERENCE\n* XENON PHARMACEUTICALS INC - INITIATED A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CROSS-OVER PHASE 1B TMS STUDY\n* XENON PHARMACEUTICALS INC - PHASE 1B TMS STUDY DATA EXPECTED IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T18:14:00.000+03:00",
    "crawled": "2018-05-16T19:22:06.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "xenon",
        "pharmaceutical",
        "inc",
        "xenon",
        "present",
        "positive",
        "xen1101",
        "tm",
        "pharmacodynamic",
        "phase",
        "data",
        "14th",
        "eilat",
        "conference",
        "xenon",
        "pharmaceutical",
        "inc",
        "initiated",
        "randomized",
        "phase",
        "1b",
        "tm",
        "study",
        "xenon",
        "pharmaceutical",
        "inc",
        "phase",
        "1b",
        "tm",
        "study",
        "data",
        "expected",
        "second",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}